News

Private equity investments are transforming the pharmaceutical manufacturing sector, unlocking new opportunities amid shifting global market dynamics. With over 1,900 manufacturing sites across Europe, strategic acquisitions require data-driven insights to navigate compliance risks, ownership complexities, and supply chain dependencies. Discover how advanced analytics platforms empower investors to make informed M&A decisions and gain a competitive edge in this evolving landscape.

The U.S. government’s 2025 tariff policy marks a major shift by introducing a 20% tariff on pharmaceuticals imported from China, products that were previously exempt under the WTO Pharmaceutical Agreement. Additional tariffs targeting imports from the EU and India are under consideration as of April 2025. QYOBO is closely tracking these developments. Leveraging data from the QYOBO platform, we analyze the potential implications of the new tariff regime on U.S. pharmaceutical supply security, global supply chain dynamics, and strategic risks and opportunities for pharmaceutical companies. Tariffs could lead to higher drug prices, supply disruptions, and manufacturing shifts. However, generics manufacturers may face greater challenges adapting due to cost constraints and limited margins.

Amid ongoing shifts in the global pharmaceutical market — including increasing regulatory scrutiny, raw material shortages, and evolving geopolitical tensions — the industry continues to navigate a landscape of uncertainty. In 2024, global API prices have largely trended downward, with QYOBO’s platform tracking these changes for thousands of APIs, excipients, intermediates and chemicals. This analysis describes API price fluctuations, highlights shifts across therapeutic categories, and provides AI-driven price forecasts for the coming months.

The API market is evolving rapidly, with regulatory approvals on the rise and manufacturing shifting towards Asia. Over the past five years, USDMF and CEP approvals have grown significantly, reflecting increasing demand for APIs in key therapeutic areas. India and China have emerged as dominant players, reshaping the industry landscape. What do these trends mean for the future of pharmaceutical manufacturing? Explore our latest insights.

FDA drug approvals serve as the pulse of pharmaceutical innovation. Between 2015 and 2024, the FDA approved 462 new drugs – a 69% increase from the previous decade. However, annual growth has slowed, indicating that investments in drug development are outpacing new approvals.